All In Biotech

NDA 019787 · Viatris

Norvasc

Amlodipine Besylate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Oct 30, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Jul 31, 1992

Approved uses

5

Original approval plus efficacy supplements

Registered trials

656

178 Phase 3, 22 recruiting

FAERS reports

147,838

101,630 serious, 13,282 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 28, 2024.

Amlodipine besylate is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) o Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal’s or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce...

Mechanism: Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 28, 2005 Supplement 38 · Efficacy LetterLabel
  • Jan 8, 2004 Supplement 30 · Efficacy ReviewLetter
  • Jul 12, 2000 Supplement 20 · Efficacy ReviewLetter
  • Jun 14, 1996 Supplement 7 · Efficacy Review
  • Jul 31, 1992 Original approval · Type 1 - New Molecular Entity
3 products under this application
  • NORVASC · AMLODIPINE BESYLATE EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB
  • NORVASC · AMLODIPINE BESYLATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
  • NORVASC · AMLODIPINE BESYLATE EQ 2.5MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.

All 656 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue9,860
  • nausea8,456
  • diarrhoea8,041
  • dyspnoea8,012
  • drug ineffective7,201
  • pain6,914
  • dizziness6,652
  • headache6,590
  • asthenia5,824
  • pneumonia5,482
  • fall5,476
  • off label use5,428

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,379
20053,869
20064,019
20073,206
20083,180
20093,982
20105,808
20116,230
20126,673
20134,898
20146,580
20157,687
20168,465
20177,500
20187,955
20197,850
20207,320
20217,565
20229,886
20238,342
20248,301
20258,803
20266,327

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Norvasc (Amlodipine Besylate)

2024 spending

$14.5M

Beneficiaries

5,263

20,746 claims

Per beneficiary

$2,747

$9.20 per unit

View as table
YearSpending
2020$23,712,300
2021$18,209,247
2022$17,072,136
2023$16,337,514
2024$14,459,169

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,808 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.